metformin has been researched along with shikonin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Arora, S; Chaturvedi, A; Heuser, M; Joshi, G; Kumar, R; Patil, S | 1 |
| Cao, C; Fan, S; Guan, MX; Jin, H; Li, H; Li, Y; Meng, F; Sun, Y; Tan, M; Zhao, L; Zhou, Q; Zhu, L | 1 |
| Gardaneh, M; Gavidel, P; Sabouni, F; Tabari, AR | 1 |
3 other study(ies) available for metformin and shikonin
| Article | Year |
|---|---|
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
Topics: Allosteric Regulation; Allosteric Site; Carrier Proteins; Chemistry, Pharmaceutical; Glycolysis; Humans; Membrane Proteins; Protein Kinase Inhibitors; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2022 |
Inhibiting neddylation modification alters mitochondrial morphology and reprograms energy metabolism in cancer cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclopentanes; Energy Metabolism; Female; GTP Phosphohydrolases; HEK293 Cells; Humans; Metformin; Mice; Mitochondria; Mitochondrial Dynamics; Mitochondrial Membrane Transport Proteins; Naphthoquinones; Neoplasms; Oxidative Phosphorylation; Proteolysis; Pyrimidines; Ubiquitin-Activating Enzymes; Ubiquitination; Xenograft Model Antitumor Assays | 2019 |
Synergy between sublethal doses of shikonin and metformin fully inhibits breast cancer cell migration and reverses epithelial-mesenchymal transition.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Female; Humans; MCF-7 Cells; Metformin; Naphthoquinones | 2022 |